Immune-Mediated Kidney Diseases

Immune-mediated kidney diseases, such as lupus nephritis, IgA nephropathy, and ANCA-associated vasculitis, involve complex immune dysregulation leading to kidney damage. At our company, we specialize in supporting innovative therapeutic development, providing expert research services to address these challenging conditions.

Introduction to Immune-Mediated Kidney Diseases

Immune-mediated kidney diseases, driven by abnormal immune responses, pose a growing challenge in nephrology, with conditions like lupus nephritis and IgA nephropathy significantly contributing to kidney disease burden worldwide. Affecting diverse populations, these disorders can progress to chronic kidney failure without effective treatment. Advances in understanding their intricate immune mechanisms highlight an urgent need for innovative therapeutic approaches.

Pathogenesis of Immune-Mediated Kidney Diseases

The pathogenesis of immune-mediated kidney diseases involves dysregulated immune responses that lead to kidney inflammation and tissue damage. Key mechanisms include the recruitment of Th1 and Th17 immune cells, driven by cytokines like IL-23 and IL-17, which create a proinflammatory microenvironment. These processes cause progressive renal damage, highlighting the need for targeted therapies to modulate immune responses effectively.

Fig.1 IL-23/IL-17 signaling and T cell activation in immune-mediated kidney disease. (Krebs, C. F., et al., 2021)

Therapeutics Development for Immune-Mediated Kidney Diseases

Therapeutics development for immune-mediated kidney diseases aims to create targeted treatments that address the underlying immune dysregulation, reducing inflammation and preventing kidney damage. This approach focuses on innovative strategies to improve patient outcomes and address unmet medical needs.

Table1. Overview of immunomodulatory drugs and ongoing trials targeting signalling pathways and B cells in IMKD. (Odler, B., et al., 2023)

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

At our company, we are proud to offer a comprehensive range of services to support our clients in developing innovative therapies for immune-mediated kidney diseases. Our team of skilled scientists, nephrologists, and immunologists utilizes advanced technologies and deep industry expertise to accelerate the advancement of your therapeutic projects.

Therapeutic Development

• Small Molecule Drug
• Cell Therapy
• Gene Therapy
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic mRNA
• Therapeutic Protein

Diseases Model Development

• Cell-based Models
• Genetically Engineering Model
• Induced Disease Model
• Humanized Animal Model
• Syngeneic Model
• Xenograft Model

Types of Immune-Mediated Kidney Diseases

Immune-mediated kidney diseases encompass a wide range of complex disorders driven by abnormal immune responses, each with distinct pathological and immunological features. Understanding these disease types is essential for developing targeted therapies.

Our company is dedicated to offering complete, one-stop preclinical development services, covering all aspects from disease model creation to cutting-edge therapeutic research. Additionally, we provide comprehensive pharmacokinetics and drug safety evaluation services to ensure rigorous assessment and support for successful drug development.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.